TNA Therapeutics
Pre-clinicalTNA Therapeutics first-in-class oral agent-there are no other agents targeting Bcl3. TNAT-101 has shown efficacy of 95% in CRC; 75% TGI and 90% anti-metastatic efficacy in TNBC. Bcl3 is novel target and the development of TNAT-101 represents a significant commercial opportunity to treat existing diseases and prevention of new diseases.
About
TNA Therapeutics first-in-class oral agent-there are no other agents targeting Bcl3. TNAT-101 has shown efficacy of 95% in CRC; 75% TGI and 90% anti-metastatic efficacy in TNBC. Bcl3 is novel target and the development of TNAT-101 represents a significant commercial opportunity to treat existing diseases and prevention of new diseases.
Funding History
2Total raised: $19.5M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile